Orthovita, Inc. (Orthovita) is an orthobiologics and biosurgery company, which develops and markets medical devices. The orthobiologics platform offers products for the fusion, regeneration, and fixation of human bone. The biosurgery platform offers products for controlling intra-operative bleeding, also known as hemostasis. The Company’s fusion and regeneration products are based on its VITOSS Bone Graft Substitute technology and address the non-structural bone graft market with synthetic, bioactive alternatives to patient- and cadaver-derived bone tissue. Its CORTOSS Bone Augmentation Material, an injectable, polymer composite, which mimics the structural characteristics of human bone, provides the basis for its fixation portfolio. Orthovita’s hemostasis portfolio includes VITAGEL Surgical Hemostat, a collagen-based matrix that controls bleeding and facilitates healing, and VITASURE Absorbable Hemostat, a plant-based product that can be deployed quickly throughout surgery.